tbuckley/cabot-search huggingface dataset:
Abstract 19529: FUNDC1 Deficiency Exacerbates Pathological Cardiac Remodeling and Contractile Dysfunction Through Suppression of DRP1
Authors: Lifeng Wang, Hong Zhu, Nan Hu, Shuyi Wang, Yingmei Zhang, Jun Ren
Journal: Circulation (2017)

Background: FUNDC1 (Fun14 domain containing protein 1) is a mitochondrial outer membrane protein to function in the recruitment of autophagic isolated membrane to mitochondria in hypoxic conditions. However, the role for FUNDC1 in heart failure remains unknown. Methods: Wild type and FUNDC1 deficient mice were subjected to transverse aortic constriction (TAC) for 1 month. Echocardiography was employed to evaluate the heart function. Lectin-FITC (WGA) and Masson Trichrome staining were used to determine cardiac remodeling. Mitophagy was measure by TEM and Pink1-Parkin and Bnip3 were measured with Western Blot. Mitochondrial membrane potential was measured using JC-1 staining. ROS production was measured with DHE and mitoSOX. DRP1 and its S616 and S637 phosphorylation were evaluated using Western Blot. H9C2 myoblasts were employed for gain and loss of function for DRP1 using siRNA and adenovirus transfection. Results: Chronic pressure overload triggered pathological cardiac remodeling (hypertrophy and inter...
Short Communication:The Effects Chronic Acetaminophen Treatment on Age-Associated Alterations of Cardiac Function in the Female F344xBN Heart
Authors: Kevin M. Rice, Jacqueline Fannin, Nandini D.P.K. Manne, Lucy Dornon, Ravi Kumar Arvapalli, Satyanarayana Paturi, Murali K. Gadde, Paulette Wehner, Michael Hambuchen, Eric R. Blough
Journal: Clinical Cardiology and Cardiovascular Interventions (2018)

Background Although several studies have investigated the age-associated changes in male and female F344 as well as male Fischer 344/NNiaHSD x Brown Norway/BiNia F1 (F344xBN), no study to our knowledge has examined the age-associated changes in structure and function in the female F344xBN heart using echocardiographic measures. This information is crucial in determining whether or not the female F344xBN is an appropriate aging model. Additional studies have also suggested that age-associated increases in levels of oxidative stress may cause cardiac dysfunction and that chronic acetaminophen (APAP) ingestion may be protective against increased oxidative stress. On the basis of these studies we examined the function and structure of the aged female F344xBN heart in the absence and presence of chronic APAP treatment. Methods To investigate if the aging-related changes in cardiovascular structure and function can be attenuated with APAP treatment, aged (22-month old) female F344xBN rats were administered APAP (30 mg/kg body weight/day) for 8 months in drinking water and echocardiograms assessments were performed. Results Aging was associated with evidence of diastolic (impaired left ventricle relaxation time) and systolic dysfunction (fractional shortening and end systolic volume). The incidence of arrhythmias was not different with age. However, valvular dysfunction was increased. Chronic APAP treatment did not attenuate the age-associated changes in cardiac structure and function in the female F344xBN. However the occurrence of valve dysfunction with aging was significantly lowered in the APAP treated 30-month female hearts.
Abstract 10325: A Typology of Self-Care Among Older Workers With Coronary Heart Disease (CHD)
Authors: Victoria Dickson, Nicholas Warren, Jin Jun, Gail D'Eramo Melkus
Journal: Circulation (2015)

America’s workforce is aging. As a result, health problems associated with aging, like CHD present new health challenges. Self-care is essential to cardiovascular health, but how self-care behaviors vary among older workers with CHD has not been explored. Objective: To identify self-care types of aging workers with CHD and identify the characteristics and work-related determinants of self-care types. Methods: In a sample of 125 older workers with CHD, 2-step cluster analysis was used to identify patterns of similarity among self-care behaviors on the maintenance scale of the Self-Care of Heart Disease Index and the General Adherence Scale. Results: Self-care in the sample clustered best into three categories: experts, novices and inconsistent. Experts (n=34, 36.4%), reported the highest levels of self-care (89.2±6.3) and high self-efficacy (75.9±19.1). Novices (n=45, 45.5%), reported adequate self-care (74.3±8.2) but inadequate self-efficacy (59.5±20.2). Those labeled as inconsistent (n=18, 18.2%), had inadequate self-care (57.2±13.2) and marginal self-efficacy (64.6±18.7). Although all types reported medication adherence, experts were more likely to monitor symptoms, keep doctors’ appointments and engage in healthy behaviors (e.g, exercising,limiting alcohol). Those inconsistent in self-care were more likely to be overweight, not follow diet, limit alcohol or avoid cigarettes. Experts and novices were more likely to be in professional or managerial positions that afforded them increased job control. The model predicting self-care type was significant ( X 2 17.622, p=.001, Nagelkerke pseudo- R 2 =.22); self-efficacy and length of time with CHD were the only significant factors. Higher level of self-efficacy was associated with an increase in odds that subjects would be typed as expert (OR = 1.045. Length of CHD diagnosis was predictive of self-care type (experts OR=1.479; inconsistent OR=1.800). Conclusions: This typology suggests that targeted self-care interventions should focus on improving self-efficacy in self-care within the context of work especially in those with new CHD or low job control. Strategies to motivate change in specific behaviors (e.g., diet and exercise) are particularly important.
Consideration of Costs and Open-Label Studies of Erenumab—Reply
Authors: Elizabeth W. Loder, Rebecca C. Burch
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 17254: Adenosine A2A Receptor Polymorphisms and Response to Regadenoson
Authors: Rolf P Kreutz, Ronald Mastouri, Rayan Saab, Santosh Philips, Todd Skaar
Journal: Circulation (2014)

Introduction: Activation of adenosine A2A receptors induces coronary vasodilation and sympathetic activation. Regadenoson is an A2A agonist used in pharmacologic cardiac nuclear stress testing, and exhibits large variability in hemodynamic response and incidence of side effects. Common genetic variants of A2A have been associated with functional differences in neurological phenotypes. Hypothesis: We hypothesized that common polymorphisms of A2A may influence response to regadenoson during cardiac stress testing. Methods: We prospectively enrolled 268 patients undergoing resting regadenoson stress testing. Five common A2A receptor variants were analyzed by Taqman genotyping assay. SPECT technetium nuclear stress tests were performed and analyzed using the 17-segment model. Blood pressure and heart rate changes were recorded prospectively after administration of regadenoson. Results: Variants of A2A were associated with significant differences in heart rate (HR), peak systolic blood pressure (SBP), and summed stress score (Table). The association of rs2298383 (minor allele frequency (MAF)=0.49), rs5751876 (MAF=0.39), and rs3761422 (MAF=0.4) with heart rate and blood pressure at rest and peak remained significant after multivariate adjustment for demographics, race, and clinical variables. Similarly, carrier status of rs2298383, rs5751876, rs3761422, and rs2267076 (MAF=0.37) remained significantly associated with summed stress score (SSS) after multivariate adjustment. Conclusion: Common genetic variants of A2A may be associated with variability in heart rate and blood pressure response to regadenoson and extent of ischemia on nuclear myocardial perfusion imaging. Further studies are necessary to examine the influence of A2A receptor variants on diagnostic sensitivity of regadenoson nuclear stress testing.
Functionalized polymer microbubbles as new molecular ultrasound contrast agent to target P-selectin in thrombus
Authors: Bo Li, Rachida Aid-Launais, Marie-Noëlle Labour, Alina Zenych, Maya Juenet, Christine Choqueux, Véronique Ollivier, Olivier Couture, Didier Letourneur, Cédric Chauvierre
Journal: Biomaterials (2018)
Interventions for rosacea based on the phenotype approach: an updated systematic review including<scp>GRADE</scp>assessments
Authors: E.J. Zuuren, Z. Fedorowicz, J. Tan, M.M.D. Linden, B.W.M. Arents, B. Carter, L. Charland
Journal: British Journal of Dermatology (2018)

Rosacea is a common chronic facial dermatosis. Classification of rosacea has evolved from subtyping to phenotyping.To update our systematic review on interventions for rosacea.We searched CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index and ongoing trials registers (March 2018) for randomized controlled trials. Study selection, data extraction, risk-of-bias assessment and analyses were carried out independently by two authors. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess certainty of evidence.We included 152 studies (46 were new), comprising 20 944 participants. Topical interventions included brimonidine, oxymetazoline, metronidazole, azelaic acid, ivermectin and other topical treatments. Systemic interventions included oral antibiotics, combinations with topical treatments or other systemic treatments. Several studies evaluated laser or light-based treatment. We present the most current evidence for rosacea management based on a phenotype-led approach.For reducing temporarily persistent erythema there was high-certainty evidence for topical brimonidine and moderate certainty for topical oxymetazoline; for erythema and mainly telangiectasia there was low-to-moderate-certainty evidence for laser and intense pulsed light therapy. For reducing papules/pustules there was high-certainty evidence for topical azelaic acid and topical ivermectin; moderate-to-high-certainty evidence for doxycycline 40 mg modified release (MR) and isotretinoin; and moderate-certainty evidence for topical metronidazole, and topical minocycline and oral minocycline being equally effective as doxycycline 40 mg MR. There was low-certainty evidence for tetracycline and low-dose minocycline. For ocular rosacea, there was moderate-certainty evidence that oral omega-3 fatty acids were effective and low-certainty evidence for ciclosporin ophthalmic emulsion and doxycycline.
Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
Authors: Douglas B. Johnson, Justin M. Balko
Journal: Clinical Cancer Research (2018)

Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment.See related article by Lim et al., p. 1557.
Norovirus antivirals: Where are we now?
Authors: Natalie E. Netzler, Daniel Enosi Tuipulotu, Peter A. White
Journal: Medicinal Research Reviews (2018)

Abstract Human noroviruses inflict a significant health burden on society and are responsible for approximately 699 million infections and over 200 000 estimated deaths worldwide each year. Yet despite significant research efforts, approved vaccines or antivirals to combat this pathogen are still lacking. Safe and effective antivirals are not available, particularly for chronically infected immunocompromised individuals, and for prophylactic applications to protect high‐risk and vulnerable populations in outbreak settings. Since the discovery of human norovirus in 1972, the lack of a cell culture system has hindered biological research and antiviral studies for many years. Recent breakthroughs in culturing human norovirus have been encouraging, however, further development and optimization of these novel methodologies are required to facilitate more robust replication levels, that will enable reliable serological and replication studies, as well as advances in antiviral development. In the last few years, considerable progress has been made toward the development of norovirus antivirals, inviting an updated review. This review focuses on potential therapeutics that have been reported since 2010, which were examined across at least two model systems used for studying human norovirus or its enzymes. In addition, we have placed emphasis on antiviral compounds with a defined chemical structure. We include a comprehensive outline of direct‐acting antivirals and offer a discussion of host‐modulating compounds, a rapidly expanding and promising area of antiviral research.
Metabolic Imaging Reveals a Unique Preference of Symmetric Cell Division and Homing of Leukemia-Initiating Cells in an Endosteal Niche
Authors: Xiaoxin Hao, Hao Gu, Chiqi Chen, Dan Huang, Yuzheng Zhao, Li Xie, Yejun Zou, Hui Sophie Shu, Yaping Zhang, Xiaoxiao He, Xiaoyun Lai, Xiaocui Zhang, Bo O. Zhou, Cheng Cheng Zhang, Guo-Qiang Chen, Zhuo Yu, Yi Yang, Junke Zheng
Journal: Cell Metabolism (2018)
Abstract 12595: Early and Persistent Accumulation of Lipid is Associated With the Development of Thin-cap Fibroatheromas
Authors: Matthew D Saybolt, Scott M Lilly, Dhavalkumar Patel, Robert S Fenning, Robert L Wilensky
Journal: Circulation (2012)

Introduction: Rupture of a thin cap fibroatheroma (TCFA) is the dominant mechanism of acute coronary syndromes. Intravascular imaging permits the in vivo evaluation of plaque morphology and content. Serial assessment with intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS) may provide insight into the subsequent development of TCFAs. Hypothesis: We hypothesized that early and persistent accumulation of plaque lipid, detected by NIRS, predicts the future development of coronary TCFAs. Methods: Diabetes and hypercholesterolemia were induced and maintained in 18 Yorkshire pigs. Multi-vessel diagnostic evaluation was performed at 3, 6 and 9 month time points with IVUS, measuring vessel atheroma and necrotic core volumes, and NIRS to measure lipid core burden index (LCBI). At 9 months animals' histology was performed at 5-mm intervals with the results correlated to in vivo data. The relationship between LCBI and the presence or absence of TCFA was determined with analysis of variance. Results...
Abstract 16456: Loss of β-Arrestin 1-Mediated VEGFR3 Signaling Promotes the Development of Pulmonary Arterial Hypertension
Authors: Zhiyuan Ma, Yen-Rei Yu, Jeffrey Kovacs, Cristian T Badea, G. A Johnson, Howard A Rockman, Claude A Piantadosi, Sudarshan Rajagopal
Journal: Circulation (2017)

Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by inflammatory and remodeling of pulmonary arterioles, leading to right ventricular (RV) failure and death. Signaling through transmembrane receptors, such as the prostacyclin and type A endothelin receptors, is known to be important in the development of PAH and many of these receptors serve as drug targets. The multifunctional adapter proteins β-arrestin 1 (βarr1) and 2 (βarr2) regulate signaling by G protein-coupled receptors (GPCRs) and other transmembrane receptors, although the physiological importance of this regulation in different disease states is unknown. Recently, we have found that βarr1 knockout (KO) mice develop worse PAH and RV dysfunction in response to hypoxia exposure. Surprisingly, we found that the major signaling abnormalities in the lungs of these mice was not associated with GPCR signaling, but with signaling through the vascular endothelial growth factor receptor 3 (VEGFR3): there was a signifi...
Relative and absolute lung function change in a general population aged 60–102 years
Authors: Johannes Luoto, Mats Pihlsgård, Per Wollmer, Sölve Elmståhl
Journal: European Respiratory Journal (2018)

Data on longitudinal lung function change in the elderly are scarce. Uncertainty remains about whether to use absolute or relative change and how it relates to subject demographics. We studied absolute and relative forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC) change in a population-based geriatric sample using a repeated measurements model adjusted for age, sex, smoking habits, heart failure, hypertension, diabetes, coronary heart disease, educational level, occupation, alcohol consumption, C-reactive protein (CRP) and body mass index. 3736 participants aged 60–102 years completed between one and five spirometries during 13.5 years of follow-up. Lung volumes, FEV<sub>1</sub> quotient (Q) and Global Lung Initiative (GLI)-2012 and National Health and Nutrition Examination Survey (NHANES) III z-scores were presented from 6932 spirometries. Adjusted absolute change per year (95% CI) was −51.7 (−63.7–−39.9) mL for FEV<sub>1</sub> and −56.2 (−73.6–−38.8) mL for FVC. Adjusted relative change per year was −2.97 (−3.53–−2.40)% for FEV<sub>1</sub> and −2.46 (−3.07–−1.85)% for FVC. Risk factors for increased relative FVC and FEV<sub>1</sub> decline were female sex, higher age, current smoking habits, elevated CRP (nonsignificant for FEV<sub>1</sub>, p=0.057) and low educational level. For increased absolute decline the risk factors were male sex and being a current smoker for FEV<sub>1</sub> and low education for FVC. Relative but not absolute change correlated significantly with clinically relevant markers of functional status and may be superior to absolute change in risk factor analysis. Cross-sectional reduction in terms of FEV<sub>1</sub>Q was ∼1 unit per 10 years for both sexes. Proportions of subjects with results below lower limit of normal using NHANES III were close to anticipated, but were two to four times higher than expected using GLI-2012.
Abstract 18047: Patient Specific iPSC-Derived Cardiomyocytes Reveal Abnormal Signaling Pathways Underlying Hypertrophic Cardiomyopathy in Noonan Syndrome
Authors: Fabrice Jaffre, Anne Schänzer, William Pu, Amy Roberts, Andreas Hahn, Maria Kontaridis
Journal: Circulation (2017)

Background: Noonan Syndrome (NS) is caused by mutations that affect the RAS/ERK1/2-MAPK pathway. >90% of NS patients with a S257L/+ mutation in Raf1 exhibit hypertrophic cardiomyopathy (HCM). Howev...
Preliminary Results of a Phase 2a Dose Optimization Study of ASLAN003 (DHODH inhibitor) in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible for Standard Therapy; Early Signs of Activity
Authors: Stephen B Ting, Chin Hin Ng, Ashish Bajel, William YK Hwang, Shir-Jing Ho, Wee-Joo Chng, Mark McHale, Chih-Yi Hsieh, Hsuan-Jen Shih, Nicola McIntyre, Jamie Kwek, Wei-Ling Chang, Bertil Lindmark
Journal: Blood (2018)
Dual Receptor Agonist for Type 2 Diabetes
Authors: Anita Slomski
Journal: JAMA (2018)

Treatment with LY3298176, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist, resulted in better glucose control than dulaglutide, a GLP-1 receptor agonist, reported a phase 2 trial in the Lancet.
Impact of Early Diabetic Ketoacidosis on the Developing Brain
Authors: Tandy Aye, Paul K. Mazaika, Nelly Mauras, Matthew J. Marzelli, Hanyang Shen, Tamara Hershey, Allison Cato, Stuart A. Weinzimer, Neil H. White, Eva Tsalikian, Booil Jo, Allan L. Reiss, Eva Tsalikian, Michael J. Tansey, Julie Coffey, Joanne Cabbage, Sara Salamati, Nelly Mauras, Larry A. Fox, Allison Cato, Kim Englert, Kaitlin Sikes, Bruce A. Buckingham, Darrell M. Wilson, Tandy Aye, Kimberly Caswell, Ellen Ambers, Stuart A. Weinzimer, William V. Tamborlane, Amy Steffen, Kate Weyman, Melinda Zgorski, Jodie Ambrosino, Neil H. White, Ana Maria Arbelaez, Lucy Levandoski, Angie Starnes, Tamara Hershey, Allan L. Reiss, Naama Barnea-Goraly, Matthew J. Marzelli, Paul K. Mazaika, Daniel X. Peng, Roy Beck, Craig Kollman, Katrina Ruedy, Karen Winer, Mark Sperling, Dorothy M. Becker, Patricia Cleary, Carla Greenbaum, Antoinette Moran
Journal: Diabetes Care (2018)

This study examined whether a history of diabetic ketoacidosis (DKA) is associated with changes in longitudinal cognitive and brain development in young children with type 1 diabetes.
Abstract 10357: The Usefulness of Home Blood Pressure Measurement in the Diagnosis of Hypertension: A Prospective Multicenter Study
Authors: Deuk-Young Nah, Jin-Wook Chung, Jun-Ho Bae, Dong-Seok Lee, Moo-Yong Rhee
Journal: Circulation (2015)

Introduction: The major hypertension guidelines suggest methods for diagnosing hypertension by measuring the 24-hour ambulatory blood pressure (ABP) or home blood pressure (HBP) if hypertension is suspected. Hypothesis: there is no consensus of cut off values for HBP as the criterion for hypertension and also optimal duration of home blood pressure measurement (HBPM). Methods: 319 suspected hypertension patients (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, average value of three times measurements of blood pressure in the office) were included in four university hospital. The blood pressure (BP) measurement taken by patients in his/her home with HBPM device (Watch BP Home, Microlife, Swiss) and measured three times with one minute interval at morning and evening for 7 days. The 24-hour ambulatory blood pressure measurement (ABPM) was performed by Mobil-O-Graph (IEM. GmbH, Germany). The device was set to obtain BP readings at 30-minute intervals during the day and night. The definition of hypertension was as follows, SBP ≥135 mmHg or DBP ≥85 mmHg for HBPM and SBP ≥130 mmHg or DBP ≥85 mmHg for ABPM. For the analysis for diagnostic accuracy of HBPM, we used ABPM as a reference standard for the diagnosis of hypertension. Results: We decided to exclude 53 patients due to dropout or lack of valid BP measurement (valid leadings &lt;70% of tried measurements of ABPM and less than 5-days HBPM). Finally we analyzed BP measurement data of 266 patients. Dropout or invalid BP measurement was more common in ABPM than HBPM. HBP was measured at least 6 days in more than 90% patients and white coat hypertension was diagnosed more frequently in the HBPM. HBPM had a more than 98.6% positive predictive value and 46.8% negative predictive value for the diagnosis of hypertension when put the criteria on ABPM. There are no difference of diagnostic accuracy for the diagnosis of hypertension according to the 5-day, 6-day and 7-day HBPM. Conclusions: A 5-day HBPM is enough for the diagnosis of hypertension considering ABPM as a reference. The cut off value of hypertension in HBPM is same to the current guideline values (135/85 mmHg) in this study. HBPM is an effective and available method for the diagnosis of hypertension in suspected hypertensive patients.